ACKNOWLEDGEMENTS

Rocio Hurtado, PIH
Marian Loveday, MRC
Jacquelin Roberts, CDC
Dale Nordenberg, Novasando
Gail Cassell, Harvard

Jonas Steengaard, Photography

FUNDING
Department of Health, KZN
WHO
IZUMI Foundation

All MDR TB patients
TB AND M/XDR TB IS HIGHER THAN ESTIMATED

CULTURE TAKING PRACTICE VS IDENTIFIED LEVEL OF MDR TB

POST MORTEM STUDY (N=240)

- TB Rx (Cult pos) 27%
- TB Rx (Cult neg) 23%
- TB not suspected (Cult pos) 17%
- Not TB 31%
- TB suspects (Cult pos) not yet on Rx 2%

R=0.82, p=0.001

Wallengren et al. EID, 2011
WAY FORWARD IN SOUTH AFRICA

• GeneXpert roll-out as primary diagnostic tool
• Community based MDR TB treatment roll-out
• New drugs
• Capacity building in Africa
  • H3Africa
  • K-RITH
RESEARCH INITIATIVES AT K-RITH

CHILDREN
• Stool in GeneXpert (Alland)
• PK study in children on TB treatment (Bishai)

NEW BIOMARKERS
• New diagnostics / response to treatment (Bishai)

NEW DIAGNOSTIC TOOLS
• Urea breath test (Wilson)
• Phage technology (Jacobs)
• Biochips (Balagadde)

DRUG RESISTANCE
• TB Genome sequencing
• TBResist

CLINICAL TRIALS
• INH sparing regimen
  2 week EBA study
  ACTG
• New combination therapy
  PA824 – PZA – MOX
  TB Alliance

HOT SPOT SURVEILLANCE
• Lot quality assurance
  Ted Cohen, Harvard
Kristina Wallengren, PhD MPH
Head of Clinical Research
K-RITH
South Africa

kristina.wallengren@k-rith.org